CL2015000778A1 - Composición farmacéutica oral sinérgica que comprende nitazoxanida y mebendazol; proceso de preparación; y uso para el tratar parasitosis humana provocada por protozoos y helmintos. - Google Patents

Composición farmacéutica oral sinérgica que comprende nitazoxanida y mebendazol; proceso de preparación; y uso para el tratar parasitosis humana provocada por protozoos y helmintos.

Info

Publication number
CL2015000778A1
CL2015000778A1 CL2015000778A CL2015000778A CL2015000778A1 CL 2015000778 A1 CL2015000778 A1 CL 2015000778A1 CL 2015000778 A CL2015000778 A CL 2015000778A CL 2015000778 A CL2015000778 A CL 2015000778A CL 2015000778 A1 CL2015000778 A1 CL 2015000778A1
Authority
CL
Chile
Prior art keywords
nitazoxanide
mebendazole
helminths
protozoa
pharmaceutical composition
Prior art date
Application number
CL2015000778A
Other languages
English (en)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50387067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of CL2015000778A1 publication Critical patent/CL2015000778A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CL2015000778A 2012-09-27 2015-03-27 Composición farmacéutica oral sinérgica que comprende nitazoxanida y mebendazol; proceso de preparación; y uso para el tratar parasitosis humana provocada por protozoos y helmintos. CL2015000778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/055166 WO2014049397A1 (es) 2012-09-27 2012-09-27 Composición sinérgica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composición para el tratamiento de la parasitosis humana

Publications (1)

Publication Number Publication Date
CL2015000778A1 true CL2015000778A1 (es) 2015-08-21

Family

ID=50387067

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000778A CL2015000778A1 (es) 2012-09-27 2015-03-27 Composición farmacéutica oral sinérgica que comprende nitazoxanida y mebendazol; proceso de preparación; y uso para el tratar parasitosis humana provocada por protozoos y helmintos.

Country Status (10)

Country Link
US (1) US20150250765A1 (es)
EP (1) EP2902024B1 (es)
AR (1) AR092169A1 (es)
BR (1) BR112015006861B1 (es)
CL (1) CL2015000778A1 (es)
CR (1) CR20150190A (es)
MX (1) MX340272B (es)
NI (1) NI201500045A (es)
UY (1) UY34967A (es)
WO (1) WO2014049397A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2610791B1 (es) * 2016-12-22 2018-02-07 Elena TEIJEIRA PRIETO Uso del mebendazol para la eliminación de los gusanos de fuego en acuarios de arrecife
CN111494327B (zh) * 2020-06-23 2023-09-05 瑞阳制药股份有限公司 甲苯咪唑咀嚼片的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657267A (en) 1969-06-20 1972-04-18 Janssen Pharmaceutica Nv Benzimidazole carbamates
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US20050171169A1 (en) * 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby

Also Published As

Publication number Publication date
UY34967A (es) 2014-04-30
NI201500045A (es) 2016-02-16
WO2014049397A1 (es) 2014-04-03
MX340272B (es) 2016-06-30
AR092169A1 (es) 2015-03-25
EP2902024A4 (en) 2016-06-22
BR112015006861A2 (pt) 2017-07-04
BR112015006861B1 (pt) 2021-10-13
CR20150190A (es) 2015-07-09
EP2902024B1 (en) 2017-11-29
EP2902024A1 (en) 2015-08-05
US20150250765A1 (en) 2015-09-10
MX2015003941A (es) 2015-07-21

Similar Documents

Publication Publication Date Title
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CR20150326A (es) Inhibidores de autotaxina
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2015000128A1 (es) Composición para controlar enfermedades en plantas y el uso de la misma
BR112013020352A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO6811867A2 (es) Cannabinoides para uso en el tratamiento del dolor neuropático
CL2014003567A1 (es) Composición que comprende iduronato-2-sulfatasa (i2s) recombinante; formulación que la comprende; método de purificación de i2s recombinante; composición farmacéutica; y uso para tratar síndrome de hunter.
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112015027026A2 (pt) composição para uso na redução da formação de crosta e na promoção da cicatrização
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112013020359B8 (pt) Colágeno gelificável e meios para a sua provisão
CR20160432A (es) Inhibidores de las vías de señalización de wnt
TR201100150A2 (tr) Suda çözünür dozaj formları